OxyPrem wins highest level of Venture Kick support
31-07-2019 – OxyPrem is developing a non-invasive device to help prevent this by measuring brain oxygenation continuously, and alerting medical staff when levels breach normal ranges.
Currently, OxyPrem is working with key opinion leaders in 12 European countries within the SafeBoosC-III trial, which is currently assessing the benefits of brain-monitoring in a group of 1,600 preterm infants. Alongside follow-ups with clinicians, OxyPrem will obtain medical device certification and start screening for viable industry partners in the near future.
